Steve Seedhouse
Stock Analyst at Cantor Fitzgerald
(2.35)
# 2,664
Out of 5,090 analysts
10
Total ratings
77.78%
Success rate
3.87%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steve Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLTE Belite Bio | Assumes: Overweight | $154 | $151.49 | +1.66% | 1 | Nov 24, 2025 | |
| KRRO Korro Bio | Downgrades: Neutral | n/a | $6.97 | - | 1 | Nov 13, 2025 | |
| XNCR Xencor | Maintains: Overweight | $40 → $42 | $18.05 | +132.69% | 2 | Nov 6, 2025 | |
| INVA Innoviva | Maintains: Overweight | $29 → $31 | $20.76 | +49.33% | 2 | Nov 6, 2025 | |
| CAMP Camp4 Therapeutics | Initiates: Overweight | $7 | $3.41 | +105.28% | 1 | Oct 2, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Overweight | $39 → $40 | $22.05 | +81.45% | 1 | Aug 1, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Overweight | $52 | $4.23 | +1,130.77% | 1 | Jul 11, 2025 | |
| HROW Harrow | Initiates: Overweight | $76 | $46.85 | +62.22% | 1 | Jul 11, 2025 |
Belite Bio
Nov 24, 2025
Assumes: Overweight
Price Target: $154
Current: $151.49
Upside: +1.66%
Korro Bio
Nov 13, 2025
Downgrades: Neutral
Price Target: n/a
Current: $6.97
Upside: -
Xencor
Nov 6, 2025
Maintains: Overweight
Price Target: $40 → $42
Current: $18.05
Upside: +132.69%
Innoviva
Nov 6, 2025
Maintains: Overweight
Price Target: $29 → $31
Current: $20.76
Upside: +49.33%
Camp4 Therapeutics
Oct 2, 2025
Initiates: Overweight
Price Target: $7
Current: $3.41
Upside: +105.28%
Apellis Pharmaceuticals
Aug 1, 2025
Maintains: Overweight
Price Target: $39 → $40
Current: $22.05
Upside: +81.45%
Tvardi Therapeutics
Jul 11, 2025
Initiates: Overweight
Price Target: $52
Current: $4.23
Upside: +1,130.77%
Harrow
Jul 11, 2025
Initiates: Overweight
Price Target: $76
Current: $46.85
Upside: +62.22%